Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration (nAMD)

The introduction of anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age-related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date that show efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria.
Source: Survey of Ophthalmology - Category: Opthalmology Authors: Source Type: research